Sheahan AV, Ellis L. Epigenetic reprogramming: A key mechanism driving therapeutic resistance. Urol Oncol. 2018;36(8):375-379. doi:10.1016/j.urolonc.2017.12.021
Hanyuda A, Cao Y, Hamada T, et al. Body mass index and risk of colorectal carcinoma subtypes classified by tumor differentiation status. Eur J Epidemiol. 2017;32(5):393-407. doi:10.1007/s10654-017-0254-y
Hovestadt V, Ayrault O, Swartling FJ, Robinson GW, Pfister SM, Northcott PA. Medulloblastomics revisited: biological and clinical insights from thousands of patients. Nat Rev Cancer. 2020;20(1):42-56. doi:10.1038/s41568-019-0223-8
Gjoneska E, Pfenning AR, Mathys H, et al. Conserved epigenomic signals in mice and humans reveal immune basis of Alzheimer’s disease. Nature. 2015;518(7539):365-9. doi:10.1038/nature14252
Polak P, Karlić R, Koren A, et al. Cell-of-origin chromatin organization shapes the mutational landscape of cancer. Nature. 2015;518(7539):360-4. doi:10.1038/nature14221
Cherry ABC, Daley GQ. Reprogramming cellular identity for regenerative medicine. Cell. 2012;148(6):1110-22. doi:10.1016/j.cell.2012.02.031
Tsankov AM, Gu H, Akopian V, et al. Transcription factor binding dynamics during human ES cell differentiation. Nature. 2015;518(7539):344-9. doi:10.1038/nature14233
Bock C, Beerman I, Lien WH, et al. DNA methylation dynamics during in vivo differentiation of blood and skin stem cells. Mol Cell. 2012;47(4):633-47. doi:10.1016/j.molcel.2012.06.019
Roadmap Epigenomics Consortium, Kundaje A, Meuleman W, et al. Integrative analysis of 111 reference human epigenomes. Nature. 2015;518(7539):317-30. doi:10.1038/nature14248
Cancer Genome Atlas Research Network, Ley TJ, Miller C, et al. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med. 2013;368(22):2059-74. doi:10.1056/NEJMoa1301689